참고문헌
- Med. Postgrad v.29 수혈로 전파되는 바이러스 질환 김현옥
- Med. Postgrad v.29 혈장으로 만드는 의약품 이성민;김인섭
- Dev. Biol. Stand v.2 The effect of freeze-drying on the potency and stability of live varicella virus vaccine Bennett, P. S.;R. Z. Maigetter;M. G. Olson;P. J. Provost;E. M. Scatergood;T. L. Schfield
- Blood Rev. v.2 Infectious complications of blood transfusion Berkman, S. A.
- Biologicals v.26 Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process Bos, O. J. M.;D. G. J. Sunye;C. E. F. Nieuweboer;F. A. C. van Engelenburg;H. Schuitemaker;J. Over
- J. Am Chem. Soc. v.68 Preparation and properties of serum and ;lasma proteins. Ⅳ. A system for the separation into fractions of the proteins and lipoprotein components of biological tissues and fluids Cohn, E. J.;L. E. Strong;W. L. Hughes Jr;D. J. Mulford;J. N. Ashworth;M. Melin;H. L. Taylor
- Blood separation and plasma fractionation Viral contamination of human plasma and procedures for preventing virus transmission by plasma products Cuthbertson, B.;K. G. Reid;P. R. Foster;J. R. Harris(ed.)
- Biologicals v.24 Improvement of virus safety of a S/D-treated factor Ⅷ concentrate by additional dry heat treatment at 100℃ Dichtelmuller, H.;D. Rudnick;B. Breuer;R. Kotitschke;M. Kloft;A. Darling;E. Watson;B. Flehmig;S. Lawson;G. Frosner
- Pharmacotherapy v.16 Viral infectivity of albumin and plasma protein fraction Erstad, B. L.
- Bundesanzeiger v.84 Notice on the registration of drugs: requirements for validation studies to demomstrate the virus safety of drugs derived from human blood or plasma Federal Health Office;Paul Ehrlich Institute Federal Office for Sera and Vaccines
- Vox Sang. v.67 no.SUP. 1 Removal and inactivation of hepatitis a Virus(HAV) during processing of factor Ⅷ concentrates Hamman, J.;J. Zou;B. Horowitz
- Curr. Stud. Hematol. Blood Transfus v.56 Strategies to produce virus-safe blood derivatives Heimburger, N.;H. E. Karges
- Dev. Bio. Stand v.81 Theroretical and technical concerns in inactivation/elimination of viruses in plasma derivatives Hilfenhause, J.;M. Niedrig;T. Nowak
- Dev. Biol. Stand v.75 Introductory remark: viral safety of biologicals Horaud, F.
- Yale J. Med v.63 Blood protein derivative viral safety: observations and analysis Horowitz, B.
- Vox Sang. v.74 no.SUP. 1 Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma Horowitz, B.;A. Lazo;H. Grossberg;G. Page;A. Lippin;G. Swan
- Lancet v.2 Virus safety of solvent/detergent treated antihaemophiliac factor concentrates Horowitz, M. S.;C. Rooks;B. Horowitz;M. W. Hilgartner
- Federal Resister v.63 no.185 Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin;Availability International Conference on Harmonisation
- Biologicals v.28 Inactivation and clearance of viruses during the manufacturing of high purity factor Ⅸ Johnston, A.;A. MacGregor;S. Borovec;M. Hattarki;K. Stuckly;D. Anderson;N. H. Goss;A. Oates;E. Uren
- J. Microbiol. Biotechnol v.10 Partitioning and inactivation of viruses by cold ethanol fractionation and pasteurization during manufacture of albumin from human plasma Kim, I. S.;H. G. Eo;C. E. Chang;S. Lee
- Biotechnol. Bioprocess Eng. v.6 Removal and inactivation of human immunodeficiency virus(HIV-1) by cold ethanol fractionation and pasteurization during the manufacturing of albumin and immunoglobulins from human plasma Kim, I. S.;H. G. Eo;C. W. Park;C. E. Chang;S. Lee
- J. Microbiol v.38 Solvent/detergent inactivation and chromatographic removal of human immunodeficiency virus during the manufacturing of a high purity antihemophilic factor Ⅷ concentrate Kim, I. S.;Y. W. Choi;H. S. Woo;C. E. Chang;S. Lee
- J. Microbiol. Biotechnol v.11 Improvement of virus safety of a human intravenous immunoglobulin by low pH incubation Kim, I. S.;Y. W. Choi;S. R. Lee;H. B. Cho;H. G. Eo;H. S. Woo;C. E. Chang;S. Lee
- J. Microbiol. Biotechnol v.11 Removal and inactivation of viruses during manufacture of a high purity antihemophilic factor Ⅷ concentrated from human plasma Kim, I. S.;Y. W. Choi;S. R. Lee;H. S. Woo;S. Lee
- J. Microbiol v.39 Removal and inactivation of hepatitis A virus during manufacture of a high purity antihemophilic factor Ⅷ concentrate from human plasma Kim, I. S.;Y. W. Choi;S. R. Lee;M. S. Lee;K. H. Huh;S. Lee
- Dev. Biol. Stand v.102 Residual risk of transfusion transmitted viral infections among seronegative donors: application of the incidence/window period model Kleinman, S.
- Virology(3rd ed.) Levy, J. A.;H. Fraenkel-Conrat;R. A. Owens
- Biologicals v.22 Inactivation of hepatitis C Virus in low pH intravenous immunoglobulin Louie, R. E.;C. J. Galloway;M. L. Dumas;M. F. Wong;G. Mitra
- Transfusion v.38 Safety of human albumin as a constituent of biologic therapeutic products McClelland, D. B. L.
- Prog. Clin. Biol. Res. v.182 Measures to inactivate viral contaminants of pooled plasma products Menache, D.;D. L. Aronson
- Dev. Biol. Stand v.81 Criteria for the choice of viruses in validation studies Minor, P. D.
- Beitr. Infusionsther v.24 Inactivation of viruses and safety of stable plasma products Morgenthaler, J. J.
- Transfusion v.39 Foundling viruses and transfusion medicine Mosley, J. W.;J. Rakela
- Dev. Biol. Stand v.81 Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurization Nowak, T.;M. Niedrig;D. Bernhardt;J. Hilfenhaus
- Transfusion v.36 Virus inactivation by pepsin treatment at pH 4 of IgG solutions: tactors affecting the rate of virus inactivation Omar, A.;C. Kempf;A. Immelmann;M. Rentsch;J. J. Morgenthaler
- Biologicals v.24 The use of a microporous polyvinylidene fluoride(PVDF) membrane filter to separate contaminating viral particles from biologically important proteins Oshima, K. H.;T. T. Evans-strickfaden;A. K. Highsmith;E. W. Ades
- Dev. Biol. Stand v.88 Safety of biopharmaceuticals: a current perspective Parkman, P. D.
- Lancet v.1 Sterilization of hepatitis and HTLV Ⅲ viruses by exposure to Tri-n-Butyl phosphate and sodium cholate Prince, A. M.;B. Horowitz;B. Brotman
- Vox Sang. v.72 Human parvovirus B19 and blood products Prowse, C.;C. A. Ludlam;P. L. Yap
- Rev. Med. Virol. v.6 Virus safety of plasma products Roberts, P.
- Curr. Stud. Hematol. Blood Transf. v.56 Overview of viruses relevant to blood transfusion Schilt, U.
- Dev. Biol. Stand v.81 The significance of the blood-borne viruses: blood banking and transfusion medicine Sherwood, W. C.
- Intervirology v.23 Characteristics and taxonomy of Parvoviridae Siegl, G.;R. C. Bates;K. I. Berns;B. J. Carter;D. C. Kelly;E. Kurstak;P. Tattersall
- Transfusion v.39 The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1 Tabor, E.
- Transfusion v.35 Hepatitis C virus infection in hypogammaglobulinemic patients receiving long-term replacement therapy with intravenous immunoglobulin Taliani, G.;E. Guerra;R. Rosso;M. C. Badolato;G. Luzi;G. Sacco;R. Lecce;C. De Bac;F. Aiuti
- Note for guidance on virus validation studies: the disign, contribution and interpretation of studies validating the inactivation and removal of viruses(CPMP/BWP/268/95) The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit.;Committee for Proprietary Medicinal Products(CPMP)
- Note for guidance on plasma derived medicinal products(CPMP/BWP/269/95 rev2) The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit.;Committee for Proprietary Medicinal Products(CPMP)
- Note for guidance on quality of biotechnology products: viral safety evaluation of biotechnology products derived from cell Lines of human or animal origin(CPMP/ICH/295/95) The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit.;Committee for Proprietary Medicinal Products(CPMP)
- Dev. Biol. Stand v.88 Process scale considerations in evaluation studies and scale-up Walter, J. K.;W. Werz;W. Berthold
- Dev. Biol. Stand v.81 Theoretical considerations on viral inactivation or elimination Willkommen, H.;J. Lower